Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer
This is a open-label study in patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense paclitaxel liposome injection compared to 3-weekly regimen.
Breast Cancer
DRUG: paclitaxel liposome injection
Progression-free Survival (PFS), 24 months
Overall Response Rate, 24 months|Clinical Benefit Rate, 24 months|Adverse Events, 24 months
This is a open-label study in patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense paclitaxel liposome injection compared to 3-weekly regimen.